About Forendo Pharma
Forendo Pharma is a Healthcare company based in Turku (Finland) founded in 2013, and was acquired by Organon in November 2021. Small molecule therapeutics for reproductive health are developed. Forendo Pharma has raised $25.58 million across 5 funding rounds from investors including Finnvera, Business Finland and Karolinska Development. Its focus areas include Life Sciences, Women Health, Drugs and Reproductive Diseases.
Company details
Forendo Pharma was founded in 2013 in Turku, Finland, and operates in the biotechnology sector focused on reproductive health. Small molecule therapeutics are developed by the company to regulate sex hormone effects in a tissue-specific manner. The pipeline includes Fispemifene, a selective estrogen receptor modulator in phase II trials for male hypogonadism, and an HSD17B1 enzyme inhibitor under investigation for endometriosis treatment.
- Headquarters Turku, Finland
- Stage Acquired
- SectorsHealthcare
- Website forendo.com
- Social LinkedIn X
- Acquired by Organon (Nov 2021)
Funding Insights of Forendo Pharma
Forendo Pharma has successfully raised a total of $25.58M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $5.62 million completed in July 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $25.58M
- Total Rounds 5
- Last Round Series A — $5.62M
- Investors Count 10
All 5 funding rounds of Forendo Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2019 | $5.62M | Series A | – | Sunstone | |
| Sep 2018 | $4.63M | Series A | – | Vesalius Biocapital III | – |
| Mar 2018 | $3.69M | Debt – Conventional | – | – | |
| Oct 2014 | $15.33M | Series A | – | Novartis Venture Fund, MSVentures | |
| Jun 2013 | Series A | – | Karolinska Development, Finnvera | – |
11 investors in total: 11 institutional.
Investors in Forendo Pharma
Forendo Pharma has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Finnvera, Business Finland and Karolinska Development.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by Sunstone in early-stage European companies. | sunstone.eu | Copenhagen, Denmark | ||
Venture capital firm investing in multiple sectors | m-ventures.com | Amsterdam, Netherlands | ||
Investments are made in innovative life science companies globally. | nvfund.com | Basel, Switzerland | ||
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Venture capital investment in early-stage technology, life science, and Health startups | innovestorgroup.com | Helsinki, Finland | ||
A European life sciences venture capital investor is operated. | 2017 | vesaliusbiocapital-3.com | Strassen, Luxembourg | |
Early-stage life science investments in Sweden are targeted. | 2003 | karolinskadevelopment.com | Solna, Sweden | |
Innovation, internationalization, and investment support for businesses is provided. | 1983 | businessfinland.fi | Helsinki, Finland | |
Financial advisory for wealth management, investments, and resource planning services. | 2011 | msvfp.com | Mumbai, India | |
Loans, investments, and financial services are provided to businesses. | 1999 | finnvera.fi | Helsinki, Finland |
Investor details for Forendo Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Forendo Pharma
4 dated milestones of Forendo Pharma across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Forendo Pharma is founded.
- Funding First funding round.
- Funding Latest funding round, Series A, of $5.6M.
- Exit Acquired by Organon.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Forendo Pharma
Complete news archive for Forendo Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Forendo Pharma
Forendo Pharma was founded in 2013.
Forendo Pharma is headquartered in Turku, Finland. It is registered at Turku, Varsinais-suomi, Finland.
Forendo Pharma is a funded company, having raised a total of $25.58M across 5 funding rounds to date.
Forendo Pharma was founded in 2013 in Turku, Finland, and operates in the biotechnology sector focused on reproductive health. Small molecule therapeutics are developed by the company to regulate sex hormone effects in a tissue-specific manner. The pipeline includes Fispemifene, a selective estrogen receptor modulator in phase II trials for male hypogonadism, and an HSD17B1 enzyme inhibitor under investigation for endometriosis treatment.
Forendo Pharma has 11 investors. Key investors include Finnvera, Business Finland, Karolinska Development, MSVentures, and Sunstone.
Yes. Forendo Pharma was acquired by Organon in November 2021.